SCHEMBL5143532

SCHEMBL5143532

COc1cc2c(cc1OC)NC=CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.45
MAPT P10636 1/20 0.45
MAOA P21397 4/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.35
KDM4E B2RXH2 2/20 0.34
CHRNA7 P36544 2/20 0.34
MAOB P27338 2/20 0.34
SLC6A4 P31645 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
EGFR P00533 1/20 0.34
SRC P12931 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894922 0.82 CHRNA7 (0.51) CHRNA7KMT2AMEN1
SCHEMBL17674463 0.69 MAPT (0.45) CYP3A4MAPTMAOAALDH1A1TSHR
SCHEMBL6363808 0.68 CYP3A4 (0.43) CYP3A4MAPTMAOAALDH1A1TSHR
SCHEMBL22049240 0.67 CYP3A4 (0.52) CYP3A4MAPTMAOAALDH1A1TSHR
SCHEMBL8471543 0.67 HTR5A (0.44) CYP3A4MAPTALDH1A1ALOX15MAPK1
SCHEMBL3903265 0.65 CYP3A4 (0.50) CYP3A4MAPTMAOAALDH1A1CYP2D6
SCHEMBL1787546 0.65 MAPT (0.62) CYP3A4MAPTMAOAALDH1A1CYP2D6
SCHEMBL8470071 0.65 NQO1 (0.42) CYP3A4MAPTALDH1A1CYP2D6CYP2C9
SCHEMBL5564105 0.64 MAOA (0.49) CYP3A4MAPTMAOAALDH1A1TSHR
SCHEMBL19233828 0.64 CYP3A4 (0.48) CYP3A4MAPTMAOAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET CYP3A4 1264/4885MAPT 4161/4885MAOA 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.